Characteristics of Crohn’s disease (CD) and ulcerative colitis (UC) patients at the beginning of the study
| CD | UC | |
|---|---|---|
| *Mean (SD) for continuous variables. NS by Wilcoxon rank sum test. | ||
| †Exact text p value <0.05. | ||
| CDAI, Crohn’s disease activity index; UCAI, ulcerative colitis activity index. | ||
| Clinical activity indices (CDAI, UCAI)* | 84.6 (55.3) | 0.9 (1.3) |
| Age at onset (y)* | 35.7 (11.6) | 41.2 (12.7) |
| Previous quiescent phase (months)* | 5.0 (4.3) | 4.8 (4.1) |
| Calprotectin (μg/g) | ||
| ⩽150 | 12 (31.6%) | 20 (48.8%) |
| >150 | 26 (68.4%) | 21 (51.2%) |
| Sex† | ||
| F | 22 (57.9%) | 12 (29.3%) |
| M | 16 (42.1%) | 29 (70.7%) |
| Smoking† | ||
| Ex | 3 (7. 9%) | 15 (36.6%) |
| No | 27 (71.0%) | 22 (53.7%) |
| Yes | 8 (21.0%) | 4 (9.8%) |
| Extent | ||
| Ileitis | 27 (71.0%) | |
| Ileocolitis | 5 (13.2%) | |
| Colitis | 6 (15.8%) | |
| Proctosigmoiditis | 28 (68.3%) | |
| Left sided colitis | 6 (14.6%) | |
| Pancolitis | 7 (17.1%) | |
| Therapy | ||
| Azathioprine | 2 (5.3%) | 2 (4.9%) |
| Mesalazine | 32 (84.2%) | 39 (95.1%) |
| No therapy | 4 (10.5%) | 0 (0%) |
| Surgery | ||
| No | 35 (92.1%) | 41 (100%) |
| Yes | 3 (7.9%) | 0 (0%) |